9:30 AM - 12:30 PM

BioJAMP Dermatology Ad Board


BY INVITATION ONLY

9:30 AM - 12:30 PM

CeraVe Ad Board


BY INVITATION ONLY

9:30 AM - 12:30 PM

SkinCeuticals/SkinBetter Science Ad Board


BY INVITATION ONLY

12:00 PM - 1:15 PM

Lunch

1:15 PM - 1:25 PM

Welcome Message

speaker-1

Dr. Charles Lynde

1:30 PM - 2:00 PM

The Power of Oat: Yesterday, Today & Beyond

Learning Objectives:

  • Review the components and the multifaceted benefits of colloidal oatmeal and the research supporting its effect on the moisture barrier.
  • Discuss the skin benefits of colloidal oatmeal by assessing the clinical research in various populations/skin conditions such as xerosis, eczema & pediatric patients.

speaker-1

Dr. Monica Li

speaker-2

Dr. Lauren Lam

speaker-3

Dr. Asha Patel Shah

2:05 PM - 2:35 PM

Reviewing the latest advancements in the treatment landscape for advanced cutaneous squamous cell carcinoma

This will be a case-based, interactive discussion with Dr. Claveau.

Learning Objectives:

  1. Strategies for optimizing the recognition and diagnosis of advanced Cutaneous Squamous Cell Carcinomas (cSCCs), along with the optimal referral pathways
  2. Examine the importance of a multi-disciplinary management of patients with advanced Cutaneous Squamous Cell Carcinoma, emphasizing its critical role in enhancing patient outeomes
  3. Discuss the critical role of anti-PD-L1 therapy in the comprehensive management of complex Cutaneous Squamous Cell Carcinoma cases, focusing on its efficacy, safety profile, and impact on patient outcomes.

speaker-1

Dr. Joël Claveau

speaker-2

Dr. Thusanth Thuraisingam

2:40 PM - 3:10 PM

Heads Up! A Topline Review of 52-Week Tildrakizumab Phase 3 Clinical Data in Scalp Psoriasis

Long-term data from Phase 3 clinical trials prospectively evaluating currently available biologics in the treatment of scalp psoriasis are limited. In this session, 52-week Phase 3 trial data for tildrakizumab, assessing efficacy and patient-reported outcomes in the treatment of moderate-to-severe psoriasis of the scalp, will be presented. To demonstrate how the trial data can translate into the real-world, a patient case will be shared. The session will conclude with an opportunity for the audience to pose questions.

Learning Objectives:
After attending this program, attendees will be able to:

  1. Recognize current unmet needs and challenges in the management of scalp psoriasis
  2. Apply phase 3 clinical trial data of IL-23 inhibitors in the treatment of scalp psoriasis to clinical practice
  3. Identify patients with scalp psoriasis for whom IL-23 inhibitor therapy is appropriate

speaker-1

Dr. Philippe Lefrançois

speaker-2

Dr. Maxwell Sauder

3:15 PM - 3:45 PM

Going Beyond Skin Clearance in Psoriasis – New Tools to Tackle PsO and PsA

A dermatologist and a rheumatologist will jointly present this interactive, data-driven session. The aim is to educate the audience on the available options to treat PsA and PsO, provide specialty-specific viewpoints on patient evaluation and treatment, and discuss how dermatologists and rheumatologists can collaborate and share knowledge. A variety of patient cases will be presented to anchor the data and provide relevant real-life examples and key takeaways will offer a clear and concise summary for the audience to reflect on and take back to their practice. A short question period will wrap up the session.

 

Learning Objectives
Support dermatologists’ understanding of:

  1. The latest guidelines for treating PsA in patients with PsO
  2. Where new medications fit in to current practice
  3. How dermatologists and rheumatologists can learn from each other and improve treatment for patients with PsA/PsO

Merck logo

speaker-1

Dr. Julien Ringuet

speaker-2

Dr. Michael Starr

3:50 PM - 4:20 PM

Addressing Racial/Ethnic Variations in atopic dermatitis and the role of skincare in improving outcomes

Learning Objectives:

  1. Understand skin barrier differences in various racial/ethnic Canadian populations according to the consensus from Canada’s leading ethnodermatology experts
  2. Discuss racial/ethnic variations in atopic dermatitis
  3. Discuss the relevance of skincare containing ceramides in various racial/ethnic Canadian populations
  4. Demonstrate the role of skincare containing ceramides in the management of atopic dermatitis in various racial/ethnic Canadian populations

speaker-1

Dr. Rachel Asiniwasis

speaker-2

Dr. Monica Li

4:25 PM - 4:55 PM

Name that Rash: Differentiating the dangerous from the mundane

The primary objective of this presentation is to have challenging discussion, polling, and reflection questions to help HCPs: Recognize some of the differences between GPP and skin conditions with similar presentations and provide realistic guidance on what they should do if they come across these diseases in their practice.

Learning Objectives:

  1. Recognize the signs and symptoms of generalized pustular psoriasis (GPP)
  2. Distinguish GPP from other skin conditions with similar presentations
  3. Choose treatment options to manage patients with these conditions

speaker-1

Dr. Mark Kirchhof

speaker-2

Dr. Kim Papp

5:00 PM - 5:15 PM

Current Controversy: Benzene in BPO-containing acne products

This briefing will examine the citizen petition by an independent laboratory Valisure finding excessive levels of benzene in benzoyl peroxide acne products. Understanding the methodology and the implications will provide a reasoned approach in dealing with this uncertainty for our patients.

speaker-1

Dr. Jerry Tan

5:00 PM - 7:00 PM

Welcome Reception

8:00 AM - 9:00 AM

Breakfast

9:00 AM - 9:50 AM

Game Face: Canadian Real-World Acne Edition

Join us for Game Face, a dermatologist’s game night favourite! With the evolving acne treatment landscape and the recent Health Canada approval of the acne therapy clascoterone, come navigate the gameboard and explore the real-world use of current acne treatments.

Meet our Players: Dr. John Kraft, Dr. Andrei Metelitsa and Dr. Dimitrios Kyritsis, who will be guided through the gameboard by our Host, Dr. Geeta Yadav.

How to Play: Players will roll the dice to build their acne patient profile on the board of patient characteristics. As our players move through the gameboard and build their acne patient profile, they will provide insight into their experience treating acne in Canada, including the use of clascoterone. Dr. Yadav will guide players through the game as they present and discuss their patient cases. The audience will have an opportunity to play through the Q&A at the conclusion of the session.

Learning Objectives:

  1. Understand and describe the clascoterone phase 3 and extension trial data, and how it can be applied to the Canadian acne treatment landscape
  2. Gain perspective and understanding into the real-world treatment of acne with clascoterone based on the experience of Canadian dermatologists

speaker-1

Dr. Geeta Yadav

speaker-2

Dr. John Kraft

speaker-3

Dr. Andrei Metelitsa

speaker-4

Dr. Dimitrios Kyritsis

9:55 AM - 10:25 AM

A Look into Next Generation Gentle Cleansing, Effective Treatments, Hydrating Moisturizers & Sun Care Innovation

Objectives:

  1. Evaluate the skin barrier as a dynamic sophisticated structure.
  2. Explore products, ingredients & technologies that gently & effectively cleanse, treat, moisturize & protect the skin.
  3. Describe criteria to consider when making product, ingredient & regimen recommendations to patients

speaker-1

Dr. Sonya Abdulla

10:30 AM - 11:20 AM

DermaTOOLogy: Building PsOlutions

Summary description of the session:
Psoriasis has a median disease duration of ~50 years and effective management is important to limit the burden of disease. Join us for an open session on tools and strategies for the short-term and long-term management of psoriasis, with a focus on topical treatments. Our expert speakers will review current treatments in the dermatologist’s toolbox and discuss various PsOlutions employed to manage real-world Canadian adolescent and adult cases. This open session will also explore future topical therapies, or those that are under construction, for the treatment of psoriasis. The audience will gain a better understanding of topical therapeutic tools for psoriasis and their practicality for managing different types of patient cases involving this chronic inflammatory disease.

Objectives of the session:

  1. Discuss current treatment strategies for the short-term and long-term topical management of plaque psoriasis
  2. Evaluate the practicality of topical therapeutic options in psoriasis management through real-world Canadian case studies
  3. Explore future clinical options in topical therapy

speaker-1

Dr. Ron Vender

speaker-2

Dr. Sophia Colantonio

speaker-3

Dr. George Christodoulou

11:25 AM - 11:55 AM

Adjuvant Therapy of Melanoma: update 2024

Brief session description:
In this interactive session, we will review the actual staging classification for melanoma and underline high risk groups. Major innovations have recently been made in the management of high risk stage III patients with the use of immunotherapy and targeted therapy. Adjuvant anti-PD1 immunotherapy is now indicated in Stage IIB and IIC patients and recent data on these treatment options will be presented including the side effect profile.

Objectives:

  1. Understand the importance of Adjuvant therapy for High-risk melanoma
  2. Review Adjuvant treatment options for Stage III and present the role of immunotherapy in high-risk Stage II patients
  3. Emphasis the role of dermatologists in the diagnosis, counselling and follow-up of melanoma patients

speaker-1

Dr. Maxwell Sauder

speaker-2

Dr. Joël Claveau

12:00 PM - 12:30 PM

Novel analgesic approaches for dermatological procedures

Description: This presentation will present dermatologists practicing aesthetic dermatology and/or medical dermatology with an update on methoxyflurane and its real-world application in a variety of dermatological procedures.

Session Objective: Challenge the status quo of pain management in the dermatology office.

speaker-1

Dr. Carrie Lynde

speaker-2

Dr. Andrei Metelitsa

12:30 PM - 1:15 PM

Lunch

1:15 PM -1:45 PM

Unlocking the potential, exploring OX40 signalling in atopic dermatitis (AD)

Objectives:

  • Investigate the role of OX40 expression and signaling in driving inflammation and chronicity in AD, highlighting its potential as a novel therapeutic target
  • Examine the clinical trial landscape focusing on the OX40 pathway in patients with moderate-to-severe AD

Amgen logo

speaker-1

Dr. Mark Kirchhof

speaker-2

Dr. Melinda Gooderham

1:50 PM - 2:20 PM

A CANADIAN CONSENSUS ON ANDROGENETIC ALOPECIA:​ APPROACH AND MANAGEMENT​

Objectives:

  • Present the status of Androgenetic alopecia management in Canada​
  • Discuss the need for a Canadian consensus on androgenetic alopecia​
  • Present the Canadian consensus on androgenetic alopecia ​

speaker-1

Dr. Ian Landells

speaker-2

Dr. Renita Ahluwalia

2:25 PM - 2:55 PM

Behind the 2024 Acne Guidelines: Takeaways and Recommended Implementation Strategies

The presentation will take the form of three “mini-modules” of approximately eight minutes each, followed by six minutes of questions from delegates. The modules are:

  1. Key takeaways from the recent AAD acne guidelines;
  2. Current thinking and anticipated directions of the forthcoming Canadian Acne guidelines; and,
  3. “What’s Next in Acne Therapy”: new therapies and emerging considerations for patient care.

Learning Objectives:

  1. To educate dermatologists and healthcare professionals regarding the 2024 Acne
  2. Vulgaris Guidelines, and to discuss implementing these guidelines in the Canadian healthcare setting

Bausch Health in collaboration with The Chronicle Information Resources Open Presentation.

speaker-1

Dr. Maxime Barakat

speaker-2

Aaron Sihota

speaker-3

Dr. Sonya Abdulla

3:00 PM - 3:30 PM

MELA OUT! ​ A NEW SOLUTION TO COMBAT THE STIGMA OF THE PIGMA-ENIGMA​

Objectives:

  • Present an overview on pigmentary disorders and new data assessing stigmatization​
  • Discuss the management of hyperpigmentation​
  • Present a new solution for the management of hyperpigmentation

speaker-1

Dr. Jerry Tan

speaker-2

Dr. Sonya Abdulla

3:35 PM - 4:05 PM

The reliability and predictability of isotretinoin over the years

Description:

  1. Review what has been learned using this medication.
  2. What hasn’t been learned or still requires attention.
  3. What is next for isotretinoin and the future of this medication.

Learning Objective: Review learning from using isotretinoin over the last 40 years in Canada

speaker-1

Dr. Sonya Abdulla

speaker-2

Dr. Sam Hanna

speaker-3

Dr. John Kraft

4:10 PM - 4:40 PM

Remastering the Classics: The New Era of Skincare ABC's for optimal skin health (Topical Antioxidant & Retinoid Version)

Most of us know the skincare ABC's all too well, and understand how incorporating vitamin A (retinoid), broad-spectrum sunscreen, and a vitamin C (antioxidant) makes for the perfect skin love story. However, what if in your wildest dreams there was a new perspective on these tried-and-true favorites that could revolutionize how dermatologists approach and prescribe these treatments to their patients? This open presentation challenges conventional views on photoprotection and aims to provide physicians with a comprehensive guide to the delicate art of product recommendations.
In this dynamic session, we will delve deep into the latest advances in dermatological science, exploring the published studies and clinical evidence surrounding antioxidants and retinoids in skincare. Our aim is for sparks to fly as we illuminate the pivotal role these ingredients play, not only in achieving aesthetic outcomes but in promoting overall skin health and longevity. Drawing upon their extensive clinical expertise, Dr. Mark Lupin and Dr. Jerry Tan will navigate the current landscape of AOX and retinoid recommendations, offering their updated insights and recommendations. No more cruel summers without proper environmental protection.
By attending this session, we will come out of the woods with an enhanced understanding of the current skincare landscape and future directions. Participants will gain practical tips and strategies for making informed, scientifically-backed choices when it comes to product recommendations for patients, ultimately optimizing their skin health and well-being. Are you ready for it? Together we can shake-off outdated notions and discover the new era of skincare ABC’s.

Objectives:

  • Review of existing research and clinicals on the “ABC” fundamentals of the dermatology toolkit: Vitamin A (Retinoid), Broad-spectrum sunscreen, and Vitamin C (Antioxidant).
  • Present novel understanding of these concepts and advancements in formulation of these key elements of skincare.

speaker-1

Dr. Mark Lupin

speaker-2

Dr. Jerry Tan

5:00 PM - 7:15 PM

La Roche Posay Ad Board


BY INVITATION ONLY

8:00 AM - 12:00 PM

Sun Pharma Advisory Board: Winlevi Real World Cases


BY INVITATION ONLY

8:00 AM - 12:00 PM

Vichy Advisory Board


BY INVITATION ONLY

Are you a dermatologist or a family physician?

Enjoy a complimentary e-subscription to SkinTherapyLetter®, a prestigious Dermatology journal indexed with the National Library in Washington.

Subscribe Today!